JP6097289B2 - セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物 - Google Patents

セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物 Download PDF

Info

Publication number
JP6097289B2
JP6097289B2 JP2014524111A JP2014524111A JP6097289B2 JP 6097289 B2 JP6097289 B2 JP 6097289B2 JP 2014524111 A JP2014524111 A JP 2014524111A JP 2014524111 A JP2014524111 A JP 2014524111A JP 6097289 B2 JP6097289 B2 JP 6097289B2
Authority
JP
Japan
Prior art keywords
methyl
fluoro
quinazoline
ylamino
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014524111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521696A5 (OSRAM
JP2014521696A (ja
Inventor
ジェームス エフ． ブレーク，
ジェームス エフ． ブレーク，
フイフェン チェン，
フイフェン チェン，
マーク ジョセフ シカレリ，
マーク ジョセフ シカレリ，
ジェイソン デミーズ，
ジェイソン デミーズ，
ルスタム ファルディナンド ガリー，
ルスタム ファルディナンド ガリー，
ジョン ゴーディノ，
ジョン ゴーディノ，
ルーイス ギャザード，
ルーイス ギャザード，
ロバート ジェイ． カウス，
ロバート ジェイ． カウス，
サミュエル キンツ，
サミュエル キンツ，
ピーター ジェイ． モーア，
ピーター ジェイ． モーア，
デイビッド エー． モレノ，
デイビッド エー． モレノ，
ジェイコブ シュワルツ，
ジェイコブ シュワルツ，
クリストファー エス． シーデム，
クリストファー エス． シーデム，
エリー エム． ウォーレース，
エリー エム． ウォーレース，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2014521696A publication Critical patent/JP2014521696A/ja
Publication of JP2014521696A5 publication Critical patent/JP2014521696A5/ja
Application granted granted Critical
Publication of JP6097289B2 publication Critical patent/JP6097289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014524111A 2011-08-04 2012-08-03 セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物 Active JP6097289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515165P 2011-08-04 2011-08-04
US61/515,165 2011-08-04
PCT/US2012/049551 WO2013020062A1 (en) 2011-08-04 2012-08-03 Quinazoline compounds as serine/threonine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2014521696A JP2014521696A (ja) 2014-08-28
JP2014521696A5 JP2014521696A5 (OSRAM) 2015-09-17
JP6097289B2 true JP6097289B2 (ja) 2017-03-15

Family

ID=47003195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014524111A Active JP6097289B2 (ja) 2011-08-04 2012-08-03 セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物

Country Status (11)

Country Link
US (1) US9187462B2 (OSRAM)
EP (1) EP2739618B1 (OSRAM)
JP (1) JP6097289B2 (OSRAM)
KR (1) KR101979042B1 (OSRAM)
CN (1) CN103958502B (OSRAM)
BR (1) BR112014002675A2 (OSRAM)
CA (1) CA2844058A1 (OSRAM)
ES (1) ES2552989T3 (OSRAM)
MX (1) MX340756B (OSRAM)
RU (1) RU2014108140A (OSRAM)
WO (1) WO2013020062A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013143839A (ru) 2011-02-28 2015-04-10 Эррэй Биофарма Инк. Ингибиторы сериновых/треониновых киназ
MX340756B (es) 2011-08-04 2016-07-25 Array Biopharma Inc Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
PT2820009T (pt) 2012-03-01 2018-04-12 Array Biopharma Inc Inibidores de serina/treonina quinases
HK1210174A1 (en) * 2012-08-27 2016-04-15 Array Biopharma, Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
CA2884766A1 (en) 2012-10-16 2014-04-24 Daniel Jon Burdick Serine/threonine kinase inhibitors
CN103254142B (zh) * 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EA031243B1 (ru) 2013-12-06 2018-12-28 Дженентек, Инк. Ингибиторы серин/треонинкиназ
CN105980387B (zh) * 2013-12-30 2019-04-19 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
CA2934679C (en) 2013-12-30 2023-02-28 Genentech, Inc. Serine/threonine kinase inhibitors
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
WO2019051296A1 (en) 2017-09-08 2019-03-14 Genentech, Inc. DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
KR20210040368A (ko) 2018-06-29 2021-04-13 킨네이트 바이오파마 인크. 사이클린 의존성 키나제의 억제제
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
EP4048261A4 (en) 2019-10-25 2023-11-22 Merck Sharp & Dohme LLC N-(HETEROARYL)-QUINAZOLINE-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
CN115448864B (zh) * 2022-08-26 2023-12-22 上海方予健康医药科技有限公司 3-氟-3-（1-羟乙基）吡咯烷-1-羧酸叔丁酯的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
BR9713863A (pt) 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
BR0108611A (pt) 2000-02-25 2003-05-06 Hoffmann La Roche Moduladores de receptor de adenosina
ATE284712T1 (de) 2000-04-26 2005-01-15 Eisai Co Ltd Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2485166A1 (en) 2002-05-21 2003-12-04 Amgen Inc. Substituted pyrimidinone and pyridinone compounds
JP4530852B2 (ja) 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
EP1742634B1 (en) 2004-04-13 2010-10-27 ICAgen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
US20070078135A1 (en) 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
MX2008010635A (es) 2006-02-16 2008-10-28 Schering Corp Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
JP2009535393A (ja) * 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
ATE530540T1 (de) 2006-08-23 2011-11-15 Pfizer Prod Inc Pyrimidonverbindungen als gsk-3-inhibitoren
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
BRPI0720635A2 (pt) 2006-12-22 2014-01-07 Novartis Ag Compostos orgânicos e seus usos
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
JP2011503006A (ja) 2007-11-06 2011-01-27 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性複素環アミン
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
BRPI0913966A2 (pt) 2008-06-27 2015-11-17 Novartis Ag compostos orgânicos
US8940891B2 (en) 2008-12-08 2015-01-27 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
RU2013143839A (ru) 2011-02-28 2015-04-10 Эррэй Биофарма Инк. Ингибиторы сериновых/треониновых киназ
MX340756B (es) 2011-08-04 2016-07-25 Array Biopharma Inc Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
PT2820009T (pt) 2012-03-01 2018-04-12 Array Biopharma Inc Inibidores de serina/treonina quinases
HK1210174A1 (en) 2012-08-27 2016-04-15 Array Biopharma, Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases

Also Published As

Publication number Publication date
EP2739618A1 (en) 2014-06-11
RU2014108140A (ru) 2015-09-10
CN103958502A (zh) 2014-07-30
WO2013020062A1 (en) 2013-02-07
MX2014001389A (es) 2014-11-13
EP2739618B1 (en) 2015-09-16
US9187462B2 (en) 2015-11-17
KR20140062057A (ko) 2014-05-22
HK1199021A1 (zh) 2015-06-19
KR101979042B1 (ko) 2019-05-15
CN103958502B (zh) 2016-02-10
ES2552989T3 (es) 2015-12-03
BR112014002675A2 (pt) 2017-02-21
HK1199248A1 (zh) 2015-06-26
MX340756B (es) 2016-07-25
US20150087664A1 (en) 2015-03-26
JP2014521696A (ja) 2014-08-28
CA2844058A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
JP6097289B2 (ja) セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
JP7579414B2 (ja) 縮合環化合物
JP6378182B2 (ja) 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
JP6085866B2 (ja) セリン／トレオニンキナーゼインヒビター
TW201803854A (zh) 經胺取代之芳基或雜芳基化合物
TWI557126B (zh) 絲胺酸／蘇胺酸激酶抑制劑
WO2023025320A1 (zh) 含氮杂环类衍生物抑制剂、其制备方法和应用
KR20130118731A (ko) 항증식성 질환 치료에 사용하기 위한 ｐｉ3ｋ 억제제로서 피페라지노트리아진
RU2783706C1 (ru) Соединения с конденсированными кольцами
HK1199248B (en) Quinazoline compounds as serine/threonine kinase inhibitors
HK1199021B (en) Quinazoline compounds as serine/threonine kinase inhibitors
HK40041215B (zh) 稠环化合物
HK40057478B (zh) Hpk1抑制剂及其使用方法
HK1227022A1 (en) Serine/threonine kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160505

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170217

R150 Certificate of patent or registration of utility model

Ref document number: 6097289

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250